Business Wire

Wizz Air Tops Major Airline Emissions Rankings

2.7.2025 11:00:00 CEST | Business Wire | Press Release

Share

Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/

The top 20 Major airlines globally, ranked by lowest CO2/ASK

Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report.

The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments. The rankings performance use Cirium's EmeraldSky platform, which achieved ISAE 3000 Reasonable Assurance from PricewaterhouseCoopers (PwC) and official accreditation from the Rocky Mountain Institute (RMI).

Wizz Air, Frontier, and Pegasus Top 3; The Top 20 Major Airlines Ranked by CO2 Emissions/ASK

The top 20 Major airlines globally are presented in the corresponding tables.

Of note is the performance of Indigo, top in Asia, Volaris, top in Latin America and the Caribbean, and Jetstar, for its performance in Australia.

The CO2/ASK Emissions of the World’s Largest Airlines

Cirium’s reporting also ranked the 10 largest airlines in the world by ASK. At the head of the table is Ryanair, followed by Southwest Airlines, and Delta Air Lines. Each of the major U.S. carriers earned spots at the table, while Turkish Airlines, Qatar Airlines and Emirates rounded out a group of primarily long-haul operators.

Enabling Fair Comparison Across the Industry

“For the first time, airlines can compare their emissions performance using a consistent, verified methodology,” said Jeremy Bowen, CEO at Cirium. "EmeraldSky provides the industry-standard benchmark that enables fair comparison and meaningful progress tracking."

The comprehensive Review analyzed global operations using dual-accredited methodology, with the full report containing extensive findings across:

  • Global Category Rankings showing the top 20 Major airlines and the World’s 10 largest airlines by CO₂ per Available Seat Kilometer
  • Regional Performance breakdowns showing which airlines excel on intra-region and inter-region routes
  • Route-Level Improvements identifying specific airport pairs with the greatest efficiency gains
  • Operational Insights revealing how fleet composition, load factors, and route optimization drive performance differences

The Review provides comprehensive operational insights that support industry-wide efficiency improvements, offering actionable intelligence for aviation stakeholders committed to sustainability progress.

Setting New Industry Transparency Standards

EmeraldSky's methodology achieved the highest level of assurance under International Standard on Assurance Engagements through rigorous independent review. The Rocky Mountain Institute's accreditation under the Pegasus Guidelines validates the approach for climate-aligned aviation financing, enabling banks and investors to make informed decisions based on verified emissions data.

This standardized approach addresses aviation's fragmented sustainability reporting, where inconsistent methodologies have made meaningful comparisons impossible. The verified benchmark enables airlines to assess their operational efficiency accurately, investors to evaluate performance reliably, and corporations to report Scope 3 emissions with confidence.

Quarterly Updates Drive Accountability

The Flight Emissions Review will be updated quarterly, tracking performance changes and operational improvements across the industry. With hundreds of data points and detailed analysis across multiple categories, the report provides the most comprehensive view of aviation emissions performance available.

Access the Complete Rankings and Analysis

The full Flight Emissions Review, including detailed carrier rankings, regional breakdowns, route-specific analysis, and operational insights, is available for download at www.cirium.com/flight-emissions-review.

Notes to Editors

* Available Seat Kilometers (ASK) is a metric in the airline industry that represents the total passenger capacity of an airline

About Cirium

Cirium® is the world’s most trusted source of aviation analytics. The company delivers powerful data and cutting-edge analytics to empower a wide spectrum of industry players. It equips airlines, airports, travel enterprises, aircraft manufacturers, and financial entities with the clarity and intelligence they need to optimize their operations, make informed decisions, and accelerate revenue growth.

Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

Download the complete Flight Emissions Review with full rankings, regional analysis, and operational insights at www.cirium.com/flight-emissions-review

View source version on businesswire.com: https://www.businesswire.com/news/home/20250702342529/en/

Contacts

Media Contact:
Mike Arnot, Cirium spokesperson
Mike@Juliettalpha.com
+1 (212) 518-4796

Callum McGoldrick
cirium@pc.agency
+44 (784) 2971398

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye